

RESEARCH ARTICLE

Open Access

Development of cross-resistance by *Aspergillus fumigatus* to clinical azoles following exposure to prochloraz, an agricultural azole

Isabel Faria-Ramos¹, Sofia Farinha¹, João Neves-Maia¹, Pedro Ribeiro Tavares¹, Isabel M Miranda^{1,2,3}, Leticia M Estevinho⁴, Cidália Pina-Vaz^{1,2,3,5} and Acácio G Rodrigues^{1,2,3,6*}

Abstract

Background: The purpose of this study was to unveil whether azole antifungals used in agriculture, similar to the clinical azoles used in humans, can evoke resistance among relevant human pathogens like *Aspergillus fumigatus*, an ubiquitous agent in nature. Additionally, cross-resistance with clinical azoles was investigated. Antifungal susceptibility testing of environmental and clinical isolates of *A. fumigatus* was performed according to the CLSI M38-A2 protocol. *In vitro* induction assays were conducted involving daily incubation of susceptible *A. fumigatus* isolates, at 35°C and 180 rpm, in fresh GYEP broth medium supplemented with Prochloraz (PCZ), a potent agricultural antifungal, for a period of 30 days. Minimal inhibitory concentrations (MIC) of PCZ and clinical azoles were monitored every ten days. In order to assess the stability of the developed MIC, the strains were afterwards sub-cultured for an additional 30 days in the absence of antifungal. Along the *in vitro* induction process, microscopic and macroscopic cultural observations were registered.

Results: MIC of PCZ increased 256 times after the initial exposure; cross-resistance to all tested clinical azoles was observed. The new MIC value of agricultural and of clinical azoles maintained stable in the absence of the selective PCZ pressure. PCZ exposure was also associated to morphological colony changes: macroscopically the colonies became mostly white, losing the typical pigmentation; microscopic examination revealed the absence of conidiation.

Conclusions: PCZ exposure induced *Aspergillus fumigatus* morphological changes and an evident increase of MIC value to PCZ as well as the development of cross-resistance with posaconazole, itraconazole and voriconazole.

Keywords: *Aspergillus fumigatus*, Cross-resistance, Clinical and agricultural azoles

Background

The ubiquitous saprophytic mould *Aspergillus fumigatus* is known to cause a spectrum of diseases in humans, including allergic syndromes, noninvasive infections, and invasive aspergillosis, a condition associated with significant morbidity and mortality [1]. *A. fumigatus* is one of the human pathogenic fungi that have a natural habitat in the environment, including soil and plants [2]. Some members of the azole drug class, which includes voriconazole (VRC) and posaconazole (POS), have been shown

to be effective in the treatment of invasive aspergillosis [3], and for a long time, azole resistance among clinical *A. fumigatus* isolates was considered to be an uncommon finding. However, multiazole resistance is emerging and is increasingly recognized as a cause of treatment failure [4,5]. In agriculture, thousands of tons of azoles are sold annually for the purpose of plant protection, either to prevent or to control fungal growth that can cause extensive loss of crops or to ease the problem of postharvest spoilage of plants and fruits [6]. The mechanism of action of all azoles - irrespectively of their chemical structure and variable biological properties - is based on its interference with the activity of fungal lanosterol 14 alpha-demethylase, an enzyme encoded by *Cyp51A* gene in *A. fumigatus* that is responsible for the transformation

* Correspondence: agr@med.up.pt

¹Microbiology Department, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal

²Cardiovascular Research & Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal

Full list of author information is available at the end of the article

of lanosterol in ergosterol, an essential component of the fungal cytoplasmic membrane. The inhibition of ergosterol formation results in cell membrane disorganization and impairment of fungal growth. Therefore, azoles are considered fungistatic rather than fungicidal, and it is well known that a strong and persistent antimicrobial pressure can lead to the selection of resistant clones, particularly if the drug effect is static rather than microbicidal [7]. Since azoles are the mainstay treatment for both human and agricultural fungal diseases, a major concern is the predictable emergence of cross-resistance to clinical *A. fumigatus* isolates that is already observed in several countries, driven by the massive use of azole fungicides in agriculture, which have the same mechanism of action as those used in humans [7-11]. The aim of our study was to investigate whether Prochloraz (PCZ), an azole extensively used in agriculture, could be associated with the development of cross-resistance to clinical azoles among *A. fumigatus*.

Results and discussion

The three isolates developed a progressive increment of PCZ minimal inhibitory concentrations (MIC) value. In addition, a concomitant increase of the MIC of VRC, POS and Itraconazole (ITZ) was also observed (Table 1). During the induction assay, MIC of PCZ increased 256 times from day 0 until day 30. Concerning the clinical azoles, cross-resistance was developed since all isolates changed from a susceptible to a resistant phenotype, according to Meletiadis and colleagues [12].

Table 1 Susceptibility pattern of tested *A. fumigatus* isolates to Prochloraz and clinical azoles

<i>A. fumigatus</i> isolate	Time of exposure (days)	MIC (mg/L)				
		PCZ	VRC	POS	ITZ	FLC
LMF05	0	0.125	0.125	0.25	2	>64
	10	0.25	0.25	0.5	2	>64
	20	8	2	1	4	>64
	30	32	8	2	8	>64
	Ø30	32	2	2	2	>64
LMF11	0	0.125	0.25	0.125	0.5	>64
	10	0.125	2	0.25	1	>64
	20	8	8	1	2	>64
	30	32	>16	4	4	>64
	Ø30	32	2	1	0.5	>64
LMN60	0	0.25	0.25	0.125	0.25	>64
	10	4	8	0.25	1	>64
	20	8	8	0.5	2	>64
	30	64	>16	4	4	>64
	Ø30	64	2	1	0.25	>64

PCZ, Prochloraz; VRC, Voriconazole; POS, Posaconazole; ITZ, Itraconazole; FLC, Fluconazole; Ø, MIC after 30 days of culture in the absence of PCZ.

There are several studies that have characterized azole resistance in *A. fumigatus*, and most recently some addressed the possible cross-resistance between environmental and medical azoles [8-11]. Our study demonstrated the time frame between the introduction of a widely used agricultural antifungal and the emergence of cross-resistance to medical triazoles. During the induction assay, we found that besides the emergence of cross-resistance, PCZ exposure caused marked morphological colony changes, both macroscopically and microscopically. Macroscopic modification of the pigmentation of *A. fumigatus* colonies, changing from the original green colour to white (Figure 1A, B and C) was remarkable at the beginning of the assay. With the increase of MIC values of PCZ the colonies became scarcer, smaller and totally white (Figure 1C). Microscopic examination showed a progressive absence of conidiation: the original strain (Figure 1A) showed normal microscopic features regarding conidiation (Figure 2A) while almost white colonies (Figure 1B) showed nearly complete absence of conidiation (Figure 2B). The totally white mycelia (Figure 1C) corresponded solely to hyphae and immature little conidiophore structures without conidia (Figure 2C). These changes in pigmentation and in conidiation as a consequence of exposure to azoles have already been reported. Varanasi and colleagues speculate that azoles may bind to a phytochrome-like regulatory molecule inhibiting the initiation and subsequent development of conidiophores in *Aspergillus* species [13]. Such mechanism of action could also explain the different levels of inhibition displayed by other tested azoles and why echinocandins and polyenes did not show this effect [13]. Notably, such morphological changes may be responsible for laboratorial diagnostic misidentification of the fungal genus/species [14]. The high MIC values for PCZ that were achieved *in vitro* maintained stable following removal of the selective pressure of the drug. For VRC, the MIC value decreased only after 30 days of incubation without the selective pressure, changing the susceptibility phenotype from resistant to intermediate. For POS, the developed MIC value also decreased but not enough to change the phenotype of resistance. Regarding ITZ, for both LMF11 and LMN60, it was observed the complete reversibility of the resistant phenotype in the absence of PCZ, ie, the MIC reverted to the initial value (susceptible). However, strain LMF05 had, since day zero, ITZ MIC of 2 mg/L, which falls in resistant category. In all the isolates conidiation reappeared together with the typical green colour of mature colonies following the removal of PCZ.

Since PCZ was responsible for the emergence of stable resistance to itself and to very important medical triazoles in *A. fumigatus*, a resistance mechanism may have been developed. Previous reports describe *cyp51A* mutation, efflux pump overexpression and/or target up-regulation as the main mechanisms responsible for



Figure 1 Photographs of Sabouraud dextrose agar plates showing macroscopic morphological changes of colonies of *A. fumigatus* following exposure to subinhibitory concentration of PCZ. **A.** Initial morphological aspect (control). **B.** After fifteen days. **C.** After thirty days.

such resistance [15-17]. A clonal expansion of isolates harbouring the TR34/L98H mutation has been reported across several countries [15-18]. Interestingly, besides the fact that these resistant isolates are less genetically variable than susceptible ones, no impact on fitness was observed [18]. The phenotypic results (Figures 1 and 2) and the stability of the developed resistance (Table 1) herein reported suggest the same. Future studies aiming to assess the underlying molecular resistance mechanisms, not only from these induced resistant strains but also from isolates with naturally high MIC values to PCZ and resistant to medical azoles without previous *in vitro* induction, will certainly be our next step. Meanwhile, our study suggests that the abuse of azole antifungals in nature may cause serious human health problems since azole-resistance and cross-resistance has the potential to further compromise the efficacy of clinical azoles in the future [4,17-20]. Furthermore, we can speculate that the exposure of clinically relevant moulds other than *A. fumigatus* to agricultural azoles may also be associated with the emergence of cross-resistance to clinical azoles. Several compounds are being tested in order to

find new antifungal alternatives, anticipating the possible loss of efficacy of clinical azoles [21]. On the other hand, efforts should be made to find safer compounds to use in agriculture.

Conclusions

In order to assess the real dimension of *Aspergillus* resistance, a susceptibility test should be performed in all isolates from patients with *Aspergillus* infection. Moreover, for patients with severe infection initial combination therapy may be considered in geographical areas with high prevalence of environmental azole resistant isolates. Ultimately, surveillance studies in both clinical and in environment settings should be conducted in order to provide updated local data regarding susceptibility profiles.

Methods

Organisms

Two clinical isolates of *A. fumigatus*, LMF05 and LMF11, and one environmental *A. fumigatus* isolate (LMN60, recovered from a garden nearby the hospital), were used in this study. The isolates were identified as belonging to *A.*




Figure 2 Photomicrographs of *Aspergillus fumigatus* colonies using the cellotape flag technique preparation with lactophenol cotton blue staining. Microscopic morphological changes in the development of conidiation of *A. fumigatus* following exposure to subinhibitory concentration of PCZ. **A.** Initial morphological aspect (control). **B.** After fifteen days. **C.** After thirty days.

fumigatus species by macroscopic and microscopic morphology, the ability to grow at 48°C and by using MALDI-TOF MS to accurately discriminate *A. fumigatus* from a new sibling species *A. lentulus*, which cannot be distinguished by morphological characteristics or growth peculiarities [22]. Long-term preservation of conidial suspensions of the isolates was made in a GYEP medium (2% glucose, 0.3% yeast extract, 1% peptone) broth supplemented with 10% glycerol and stored at -80°C. Working cultures were subsequently maintained during 2 weeks on Sabouraud dextrose agar slants and plates at 4°C.

Antifungal agents and susceptibility profile

PCZ is an imidazole and one of the main drugs used within European Union for crop protection [23]. This ergosterol biosynthesis inhibitor was selected as a representative of agricultural azoles after a previous MIC screening, where it showed to be the less active agricultural drug on the selected strains, ie, it had the lower MIC values, which was a prerequisite for this induction experiment. Fluconazole (FLC), VRC, POS and ITZ were selected as clinical azoles. PCZ was resuspended in 80% acetone solution at a final concentration of 5 mg/L. Clinical azoles were dissolved in dimethylsulphoxide (DMSO) to obtain stock solutions of 10 mg/L. All drugs were stored at -20°C. Broth microdilution susceptibility assay was performed according to the Clinical and Laboratory Standards Institute M38-A2 protocol in order to evaluate the initial MIC of PCZ and of all the clinical azoles [24]. Drug concentration ranged from 0.125 to 64 mg/L of FLC and PCZ; and 0.0313 to 16 mg/L of POS, VRC and ITZ. *A. fumigatus* ATCC 46645 was included for quality control of susceptibility testing. Also, FLC was used as control, since *A. fumigatus* shows a non-susceptible phenotype and MIC is most often above 64 mg/L for this species. MIC of azoles was defined as the lowest concentration of the drug that produced no visible growth following 48 hours of incubation. MIC determination was repeated at least twice.

In vitro induction experiments

Induction experiments were performed with the agricultural azole PCZ. *A. fumigatus* isolates were grown on Sabouraud dextrose agar at 35°C for 72 h; conidia were harvested by flooding the surface of the slants with phosphate-buffered saline (PBS) containing 0.025% (vol/vol) tween 80 while gently rocking. The conidial suspensions were then adjusted using specific spectrophotometric readings at 550 nm to a final concentration of 5×10^4 conidia per milliter [25]; one milliter of each distinct isolate suspension was transferred to 9 ml of GYEP broth supplemented with sub-inhibitory concentrations of PCZ (0.06 mg/L for both LMF05 and LMF11; 0.125 mg/L for LMN60) and incubated overnight at

35°C with agitation (180 rpm). Daily, after vigorous vortexing for 60 seconds, one milliter from each culture was transferred to fresh GYEP medium supplemented with PCZ and in parallel, 1 ml of culture was added with 10% glycerol and frozen at -80°C. This procedure was repeated along thirty consecutive days.

Susceptibility testing/ Stability of in vitro developed resistance phenotype

MICs of PCZ were determined every ten days along the thirty days of induction assay. No official breakpoints are yet defined for PCZ; therefore, whenever a marked MIC increase was observed (four fold the initial PCZ MIC), the MIC values of clinical antifungals were determined.

In order to assess the stability of the developed MIC increment to PCZ and of the developed cross-resistance to clinical azoles, the induced strains were afterwards sub-cultured for an additional thirty days in the absence of the drug and MIC values re-determined, as previously described.

Culture macro and micro morphology

Along the induction process, every two days, a loopful was inoculated in Sabouraud Agar slants to check for viability and purity of culture. Macro and microscopical growth characteristics were registered. Colony morphology and pigmentation were recorded photographically using a Reflex Nikon D3200 Camera and images were processed by Adobe Photo Deluxe Image Processing Program. Microscopic images of hyphae changes from the original *A. fumigatus* strain and from the resistant induced strain were captured with a Zeiss-Axioplan-2 microscope equipped with Axio Cam. AxioVision 3.0 digital imaging software was used for editing.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

IFR, IMM and AGR: conceived the study and designed the experiments; IFR and SF: performed the experiments; IFR, SF, JNM and PRT: analysed the data; IMM, LME, CPV and AGR: Contributed with reagents/material and analysis tools; IFR, SF, IMM and AGR: wrote and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

IFR and IMM are supported by FCT (Fundação Ciência e Tecnologia). IFR is supported by FCT PhD grant (SFRH/BD/91155/2012). IMM is supported by FCT, Ciência 2008 and co-financed by the European Social Fund. The authors would like to thank Isabel Santos for the excellent technical assistance. Part of the results was presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, held San Francisco, USA, September 2012.

Author details

¹Microbiology Department, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. ²Cardiovascular Research & Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal. ³CINTESIS - Center for Health Technology and Services Research, Faculty of Medicine of the University of

Porto, Portugal. ⁴Department of Biology and Biotechnology, CIMO-Mountain Research Center, Agricultural College of Bragança, Polytechnic Institute of Bragança, Porto, Portugal. ⁵Microbiology Department, Centro Hospitalar de São João, Porto, Portugal. ⁶Burn Unit, Centro Hospitalar de São João, Porto, Portugal.

Received: 6 March 2014 Accepted: 4 June 2014

Published: 11 June 2014

References

- Denning DW, Riniotis K, Dobrashian R, Sambatakou H: **Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review.** *Clin Infect Dis* 2003, **37**:S265–S280.
- Shapiro RS, Robbins N, Cowen LE: **Regulatory circuitry governing fungal development, drug resistance, and disease.** *Microbiol Mol Biol Rev* 2011, **75**:213–267.
- Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik J, Wingard JR, Patterson TF: **Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America.** *Clin Infect Dis* 2008, **46**:327–360.
- Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW: **Frequency and evolution of Azole resistance in *Aspergillus fumigatus* associated with treatment failure.** *Emerg Infect Dis* 2009, **15**:1068–1076.
- Arikan-Akdagli S: **Azole resistance in *Aspergillus*: global status in Europe and Asia.** *Ann N Y Acad Sci* 2012, **1272**:9–14.
- Hof H: **Critical annotations to the use of azole antifungals for plant protection.** *Antimicrob Agents Chemother* 2001, **45**:2897–2990.
- Bowyer P, Denning DW: **Environmental fungicides and triazole resistance in *Aspergillus*.** *Pest Manag Sci* 2014, **70**:173–178.
- Snelders E, Camps SM, Karawajczyk A, Schaftenaar G, Kema GH, van der Lee HA, Klaassen CH, Melchers WJ, Verweij PE: **Triazole fungicides can induce cross-resistance to medical triazoles in *Aspergillus fumigatus*.** *PLoS One* 2012, **7**:e31801.
- Snelders E, Veld RA H't, Rijs AJ, Kema GH, Melchers WJ, Verweij PE: **Possible Environmental Origin of Resistance of *Aspergillus fumigatus* to Medical Triazoles.** *Appl Environ Microbiol* 2009, **75**:4053–4057.
- Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ: **Azole resistance in *Aspergillus fumigatus*: a side-effect of environmental fungicide use?** *Lancet Infect Dis* 2009, **9**:789–795.
- Stensvold CR, Jorgensen LN, Arendrup MC: **Azole-Resistant Invasive Aspergillosis: Relationship to Agriculture.** *Curr Fungal Infect Rep* 2012, **6**:178–191.
- Meletiadiis J, Mavridou E, Melchers WJ, Mouton JW, Verweij PE: **Epidemiological cutoff values for azoles and *Aspergillus fumigatus* based on a novel mathematical approach incorporating cyp51A sequence analysis.** *Antimicrob Agents Chemother* 2012, **56**:2524–2529.
- Varanasi NL, Baskaran I, Alangaden GJ, Chandrasekar PH, Manavathu EK: **Novel effect of voriconazole on conidiation of *Aspergillus* species.** *Int J Antimicrob Agents* 2004, **23**:72–79.
- Sangoi AR, Rogers WM, Longacre TA, Montoya JG, Baron EJ, Banaei N: **Challenges and pitfalls of morphologic identification of fungal infections in histologic and cytologic specimens: a ten-year retrospective review at a single institution.** *Am J Clin Pathol* 2009, **131**:364–375.
- Verweij PE, Kema GH, Zwaan B, Melchers WJ: **Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould *Aspergillus fumigatus*.** *Pest Manag Sci* 2013, **69**:165–170.
- Fraczek MG, Bromley M, Buied A, Moore CB, Rajendran R, Rautemaa R, Ramage G, Denning DW, Bowyer P: **The *cdr1B* efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in *Aspergillus fumigatus*.** *J Antimicrob Chemother* 2013, **68**:1486–1496.
- Vermeulen E, Lagrou K, Verweij PE: **Azole resistance in *Aspergillus fumigatus*: a growing public health concern.** *Curr Opin Infect Dis* 2013, **26**:493–500.
- Chowdhary A, Kathuria S, Xu J, Meis JF: **Emergence of Azole-Resistant *Aspergillus fumigatus* Strains due to Agricultural Azole Use Creates an Increasing Threat to Human Health.** *PLoS Pathog* 2013, **9**:1003633.
- Gisi U: **Assessment of selection and resistance risk for DMI fungicides in *Aspergillus fumigatus* in agriculture and medicine: A critical review.** *Pest Manag Sci* 2014, **70**(3):352–364.
- Hof H: **Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine?** *Drug Resist Updat* 2008, **11**:25–31.
- Geronikaki A, Fesatidou M, Kartsev V, Macae F: **Synthesis and biological evaluation of potent antifungal agents.** *Curr Top Med Chem* 2013, **13**:2684–2733.
- Verwer PE, van Leeuwen WB, Girard V, Monnin V, van Belkum A, Staab JF, Verbrugh HA, Bakker-Woudenberg IA, van de Sande WW: **Discrimination of *Aspergillus lentulus* from *Aspergillus fumigatus* by Raman spectroscopy and MALDI-TOF MS.** *Eur J Clin Microbiol Infect Dis* 2014, **33**:245–251.
- European Commission: **The use of plant protection products in the European Union.** 2007 [http://epp.eurostat.ec.europa.eu/portal/page/portal/product_details/publication?p_product_code=KS-76-06-669]
- Clinical and Laboratory Standards Institute: **Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard- Second Edition.** Wayne, PA, USA: CLSI M38-A2; 2002.
- Araujo R, Rodrigues AG, Pina-Vaz C: **A fast, practical and reproducible procedure for the standardization of the cell density of an *Aspergillus* suspension.** *J Med Microbiol* 2004, **53**:783–786.

doi:10.1186/1471-2180-14-155

Cite this article as: Faria-Ramos et al.: Development of cross-resistance by *Aspergillus fumigatus* to clinical azoles following exposure to prochloraz, an agricultural azole. *BMC Microbiology* 2014 **14**:155.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

